All In MedTech

FDA Clearance Tracker · P140028

INNOVA VASCULAR SELF-EXPANDING STENT WITH DELIVERY SYSTEM

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Jul 21, 2015 (this decision)Source: openFDAMethods & limitations

PMA

The decision

FDA number
P140028
Device name
INNOVA VASCULAR SELF-EXPANDING STENT WITH DELIVERY SYSTEM
Applicant location
Maple Grove, MN
Received
Dec 10, 2014
Decided
Jul 21, 2015
Decision
Approved
Supplements
86 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code NIP

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE INNOVA VASCULAR SELF-EXPANDING STENT SYSTEM. THIS DEVICE IS INDICATED FOR: THE INNOVA VASCULAR SELF-EXPANDING STENT SYSTEM IS INDICATED TO IMPROVE LUMINAL DIAMETER IN THE TREATMENT OF SYMPTOMATIC DE-NOVO OR RESTENOTIC LESIONS IN THE NATIVE SUPERFICIAL FEMORAL ARTERY (SFA) AND/OR PROXIMAL POPLITEAL ARTERY (PPA) WITH REFERENCE VESSEL DIAMETERS FROM 4.0 MM TO 7.0 MM AND LESION LENGTHS UP TO 190 MM.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code NIP. The earliest in FDA's data is P000033, decided Apr 3, 2002.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Boston Scientific Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.